Novavax Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Moving Average Envelope

Score

-0.65

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 20 14.8 0.30% 0.43% 20.1% -11.4% -39.4%
SHORT 20 21.7 0.40% 0.57% 6.9% -11.1% -100.2%

Summary

Technical Analysis


Moving Average Envelopes are percentage-based envelopes set above and below a moving average. The moving average which forms the base for this indicator can be a simple or exponential moving average. Each envelope is then set the same percentage above or below the moving average. This creates parallel bands that follow price action. With a moving average as the base Moving Average Envelopes can be used as a trend following indicator.

Calculation: Moving Average Envelope:
1) Upper Envelope: 20-day SMA + (20-day SMA x .025);
2) Lower Envelope: 20-day SMA - (20-day SMA x .025);


PROFILE: Novavax Inc (NVAX)


Stock Exchange: NASDAQ
Company: Novavax Inc
Ticker Codes: | NVAX | NASDAQ:NVAX |

About Novavax Inc (NASDAQ:NVAX):

Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Top 10:

Moving Average Envelope

Download
Company Close Change(%) Volume Value Signal
STKL Sunopta Inc 2.69 13 767,118 22.17 BULLISH
ECPG Encore Capital 34.61 12 1,185,057 72.39 BULLISH
BCRX BioCryst Pharmaceuticals 2.74 8.3 11,180,169 79.69 BULLISH
NTRA Natera 37.25 7.1 2,078,137 133.55 BULLISH
KPTI Karyopharm Therapeutics 15.38 7 1,860,063 34.88 BULLISH
CRIS Curis Inc 1.23 7 256,944 34.48 BULLISH
ORBC Orbcomm 3.44 4.2 2,627,367 30.33 BULLISH
HSII Heidrick & Struggles 22.2 3.8 207,252 97.1 BULLISH
FRGI Fiesta Restaurant 9.44 3.7 499,690 98.42 BULLISH
ATRA Atara Biotherap 11.48 2.8 639,733 2.81 BULLISH